Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Xencor Inc revenues increased from $16M to $32.7M. Net loss decreased 34% to $48.4M. Revenues reflect Milestone segment increase from $500K to $14.5M, Royalties segment increase of 18% to $18.2M. Lower net loss reflects Asset impairment charges decrease of 76% to $4.9M (expense), Interest expense decrease of 10% to $8.7M (expense).